VC  ARCH Venture Partners

https://www.archventure.com/





     Office Locations:

8755 W. Higgins Rd., Suite 1025
Chicago, IL 60631
Phone: 773-380-6600
Fax: 773-380-6606

Get all office locations for this firm with a National Database subscription or Silicon Valley Database subscription.
 

Stages:

  • Early
  • Seed


 

Industries:

  • Information Technology
  • Life Sciences & Healthcare

  •  

    Description:

    Arch Venture Partners is a provider of seed and early-stage venture capital for technology firms with a special expertise in co-founding and building technology firms from startup. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. ARCH currently manages eight funds totaling nearly $2.0 billion and has invested in the earliest venture capital rounds for more than 150 companies. ARCH Venture Partners became a private venture partnership after separating from its predecessor company, ARCH Development Corporation. Formed in 1986 by the Trustees of the University of Chicago, ARCH Development Corporation was managed by ARCH founding partners. The first fund, ARCH Venture Fund I, was a $9 million fund established in 1989. ARCH announced August 2014 that its eighth venture fund closed with more than $400 million in subscriptions. ARCH Venture Fund VIII exceeded its $250 million subscription target by more than $150 million. ARCH will invest $50K to $150M in a single deal. ARCH Venture Partners announced (June of 2022) the closing of ARCH Venture Fund XII, with $2.975 billion to invest in the creation, development and funding of early stage biotechnology companies. This new fund follows the January 2021 announcement of the $1.941 Billion ARCH Venture Fund XI.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Silicon Valley Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Carol Suh Partner
    Clinton W. Bybee Co-founder and Managing Director, Emeritus
    Keith L. Crandell Co-Founder and Managing Director
    Kristina Burow Managing Director
    Mark McDonnell Managing Director, CAO & CFO

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      02/27/2024


      Matter Neuroscience


      CO


      $26,000,000


      Seed


      02/13/2024


      Areteia Therapeutics


      NC


      $75,000,000


      Series A


      02/01/2024


      Proniras


      WA


      $4,650,000


      Series B


      02/01/2024


      Basking Biosciences


      OH


      $55,000,000


      Series B


      01/23/2024


      Elephas Biosciences


      WI


      $55,000,000


      Series C


      01/04/2024


      Human Immunology Biosciences


      CA


      $95,000,000


      Series B


      11/01/2023


      Gate Bioscience


      CA


      $60,000,000


      Series A


      10/13/2023


      ROME Therapeutics


      MA


      $149,000,000


      Series B


      09/14/2023


      Generate:Biomedicines


      MA


      $273,000,000


      Series C


      08/23/2023


      Rapport Therapeutics


      MA


      $150,000,000


      Series B


      05/18/2023


      OncoResponse


      TX


      $14,000,000


      Venture


     

    Portfolio companies include:


      908 Devices
        web link


      AgBiome
        web link


      Agrivida


      Aira.IO
        web link


      Aledade
        web link


      ApoGen Biotechnologies
        web link


      Areteia Therapeutics
        web link


      Arivale
        web link


      Aspen Neuroscience


      Basking Biosciences
        web link


      Beam Therapeutics


      BlackThorn Therapeutics
        web link


      bluebird bio
        web link


      Boragen


      Boreal Genomics
        web link


      Boundless Bio
        web link


      Chiasma
        web link


      Chroma Medicine
        web link


      Codiak Biosciences


      Cytrellis Biosystems
        web link


      Denali Therapeutics


      Dewpoint Therapeutics
        web link


      eGenesis
        web link


      Elephas Biosciences
        web link


      Epirium Bio
        web link


      EQRx
        web link


      Erasca
        web link


      FogPharma
        web link


      Gate Bioscience
        web link


      Generate:Biomedicines
        web link


      Glympse Bio
        web link


      Gossamer Bio
        web link


      Grail


      Happy Health
        web link


      hC Bioscience
        web link


      HiberCell
        web link


      Homology Medicines
        web link


      Human Immunology Biosciences
        web link


      ImmuneID
        web link


      ImmusanT


      Impinj


      Insitro
        web link


      Interline Therapeutics
        web link


      Juno Therapeutics


      Just Biotherapeutics
        web link


      Karuna Pharmaceuticals
        web link


      KSQ Therapeutics
        web link


      LifeMine Therapeutics
        web link


      Locana


      Lodo Therapeutics
        web link


      Luna DNA
        web link


      LunaPBC
        web link


      Magnolia Neurosciences
        web link


      Matter Neuroscience
        web link


      Maze Therapeutics
        web link


      Metacrine
        web link


      Mindstrong Health
        web link


      Movidius
        web link


      Mozart Therapeutics
        web link


      Neumora Therapeutics
        web link


      NextCODE Health
        web link


      Nutcracker Therapeutics
        web link


      Omniome
        web link


      OncoResponse
        web link


      Pheast Therapeutics
        web link


      Pretzel Therapeutics
        web link


      Proniras
        web link


      Protillion Biosciences
        web link


      Quanterix
        web link


      Rapport Therapeutics
        web link


      ROME Therapeutics
        web link


      SAGE Therapeutics
        web link


      Sana Biotechnology


      Scholar Rock
        web link


      Semma Therapeutics
        web link


      Sienna Biopharmaceuticals
        web link


      Siluria Technologies
        web link


      Slingshot Biosciences
        web link


      Sonoma Biotherapeutics
        web link


      SonoThera
        web link


      Sorbent Therapeutics
        web link


      Synchron
        web link


      Syros Pharmaceuticals
        web link


      Theraclone Sciences
        web link


      Twist Bioscience
        web link


      Ultivue
        web link


      UNITY Biotechnology


      Verve Therapeutics
        web link


      Vir Biotechnology
        web link


      Vividion Therapeutics
        web link


      Vizgen


      Voxel8


      Walden Biosciences
        web link


     

    Recent News: